Breast Cancer
Expert treatment for breast cancer including surgery, chemotherapy, targeted therapy, hormone therapy, and radiation therapy with personalized care.
Breast Cancer
Solid Tumors
Overview
Breast cancer is the most frequently diagnosed cancer and a leading cause of cancer-related mortality among women globally. It originates in the breast tissue, typically starting in the cells lining the milk ducts (ductal carcinoma) or the lobules that produce milk (lobular carcinoma). The vast majority of cases are invasive ductal carcinoma, which has broken through the duct walls and invaded surrounding breast tissue, with the potential to spread to regional axillary lymph nodes and distant organs such as the bones, liver, lungs, and brain.
Breast cancer is a highly heterogeneous disease, classified into distinct molecular subtypes based on the presence or absence of hormone receptors (Estrogen Receptor [ER] and Progesterone Receptor [PR]) and Human Epidermal Growth Factor Receptor 2 (HER2). The subtypes include Hormone Receptor-Positive (ER+/PR+), HER2-Positive (HER2+), and Triple-Negative Breast Cancer (TNBC), which lacks all three markers and tends to be more aggressive. Early signs of breast cancer include a painless lump or thickening in the breast or underarm, changes in the size or shape of the breast, skin dimpling or puckering (peau d'orange), nipple inversion, redness or scaling of the breast skin or nipple, and abnormal nipple discharge (especially if bloody).
Systemic symptoms or localized bone pain, shortness of breath, and abdominal swelling appear in advanced metastatic stages. Understanding the molecular subtype and clinical stage is essential, as breast cancer treatment is highly personalized.
When to Consult
Upon detection of breast lump, abnormal mammogram, nipple changes, breast pain, or confirmed breast cancer diagnosis.
What to Bring
Mammogram reports, breast biopsy results, ultrasound reports, MRI reports, hormone receptor test results (ER/PR), HER2 status, Ki-67, and genetic testing if available.
Risk Factors
Causes
Treatment Options
Breast-Conserving Surgery and Mastectomy
Surgical resection is the primary curative treatment for localized breast cancer. The main approaches are Breast-Conserving Surgery (BCS), also known as a lumpectomy or partial mastectomy, which removes the tumor along with a margin of healthy tissue while preserving the breast structure; and Mastectomy, which involves the removal of the entire breast tissue. BCS is almost always followed by radiation therapy to reduce local recurrence. During surgery, evaluation of the lymph nodes is critical. This is achieved via a Sentinel Lymph Node Biopsy (SLNB), where the first few lymph nodes draining the breast are removed and examined. If cancer is found, an Axillary Lymph Node Dissection (ALND) may be performed. Breast reconstruction surgery can be done concurrently or delayed, using implants or autologous tissue flaps (e.g., DIEP or TRAM flaps).
Neoadjuvant and Adjuvant Chemotherapy
Chemotherapy uses systemic cytotoxic drugs to destroy cancer cells and is used in both early-stage and advanced breast cancer. Neoadjuvant chemotherapy is administered before surgery to shrink large or aggressive tumors (such as TNBC or HER2+), potentially allowing for breast-conserving surgery instead of mastectomy and providing information on treatment response. Adjuvant chemotherapy is given after surgery to eliminate any remaining microscopic disease and reduce recurrence. Common chemotherapy drugs include anthracyclines (Doxorubicin, Epirubicin), taxanes (Paclitaxel, Docetaxel), alkylating agents (Cyclophosphamide), and antimetabolites (5-Fluorouracil). Side effects are managed with growth factors, anti-nausea medications, and scalp cooling caps.
Endocrine (Hormone) Therapy
For patients with hormone receptor-positive (ER+ and/or PR+) breast cancer, endocrine therapy is a highly effective treatment that blocks estrogen from fueling cancer cell growth. In premenopausal women, Tamoxifen (a selective estrogen receptor modulator) is the standard treatment, often combined with ovarian function suppression using LHRH agonists (e.g., Goserelin). In postmenopausal women, Aromatase Inhibitors (AIs) such as Anastrozole, Letrozole, or Exemestane are preferred, which prevent the conversion of androgens into estrogen in peripheral tissues. Endocrine therapy is typically prescribed for 5 to 10 years in the adjuvant setting. For advanced ER+ breast cancer, endocrine therapy is often combined with targeted agents like CDK4/6 inhibitors (Palbociclib, Ribociclib, Abemaciclib).
HER2-Targeted and Precision Therapies
Targeted therapies are designed to attack specific molecular markers on breast cancer cells, significantly improving outcomes. For HER2-positive breast cancer, monoclonal antibodies like Trastuzumab and Pertuzumab target the HER2 receptor, blocking growth signals. Antibody-drug conjugates (ADCs) like Trastuzumab Emtansine (T-DM1) and Trastuzumab Deruxtecan (T-Dxd) deliver high concentrations of chemotherapy directly to HER2-expressing cells, minimizing damage to normal tissue. Small molecule tyrosine kinase inhibitors like Lapatinib, Neratinib, and Tucatinib are also used. For patients with inherited BRCA1 or BRCA2 mutations, PARP inhibitors such as Olaparib or Talazoparib offer targeted oral options. Immunotherapy (Pembrolizumab) is combined with chemotherapy for triple-negative breast cancer.
Adjuvant and Palliative Radiation Therapy
Radiation therapy utilizes high-energy X-rays to destroy cancer cells. Following breast-conserving surgery, adjuvant whole-breast irradiation is standard to eliminate residual microscopic disease. Post-mastectomy radiation may be indicated for patients with large tumors (>5 cm) or involvement of multiple lymph nodes. Techniques include External Beam Radiation Therapy (EBRT), which can be delivered via hypofractionated schedules (shorter courses with higher daily doses), and Intensity-Modulated Radiation Therapy (IMRT) to minimize exposure to the heart and lungs. Deep Inspiration Breath Hold (DIBH) is used for left-sided breast cancers to protect the heart. Palliative radiation is used to treat painful bone metastases or brain metastases.
Frequently Asked Questions
Q. What is the most effective treatment for Breast Cancer?
The most effective treatment for Breast Cancer depends on the stage, location, molecular profile of the tumor, and the patient's overall health. Dr. R. Srinath Bharadwaj provides personalized protocols including chemotherapy , immunotherapy , targeted therapy , or combination approaches.
Q. Where can I get expert treatment for Breast Cancer in Hyderabad?
You can consult Dr. R. Srinath Bharadwaj, a leading Medical Oncologist, at the American Oncology Institute, Nallagandla, Hyderabad. Call +91 91213 36638 to schedule an appointment.
Q. What documents should I bring for a Breast Cancer consultation?
Please bring all recent biopsy reports, imaging scans (CT, MRI, or PET-CT), tumor markers, blood test results, and any previous treatment or surgery details to help outline your care plan.